GlaxoSmithKline said the company’s anemia pill for patients with kidney disease was shown to have about the same side effect risk as the current standard treatment in two important patient groups, a key advantage in a tight race with rival drug developers.
Young women who were vaccinated against human papillomavirus (HPV) in their teens with an older GlaxoSmithKline product called Cervarix had up to an 87 percent lower risk of developing cervical cancer linked to the virus, a long-running English study found.
Shares of GlaxoSmithKline climbed in trading on rumors that the consumer health business it intends to spin off into a separate company next year is attracting interest from venture capitalists.
CureVac NV said on Oct. 12 the company will give up on the biotechnology firm’s first-generation Covid-19 vaccine candidate and instead focus on collaborating with GSK to develop improved mRNA vaccine technology.
According to a Wall Street Journal report, the preferred Covid-19 shot globally is the Pfizer-BioNTech vaccine.
GSK continues to increase investment in the company pipeline, build on top-line momentum for key growth drivers, and largely complete readiness for the consumer healthcare business separation.
The World Health Organization (WHO) said on Oct. 6 the only approved vaccine against malaria should be widely given to African children, potentially marking a major advance against a disease that kills hundreds of thousands of people annually.
GlaxoSmithKline announced the British pharma leader’s intention to leave the sprawling campus in Research Triangle Park, N.C. for the more compact confines of a downtown Durham, N.C. space.
Germany’s Merck KGaA and Britain’s GlaxoSmithKline on Thursday ended their collaboration on the cancer treatment bintrafusp alfa, once seen as one of Merck’s most promising experimental drugs.
In the 40 years since the HIV epidemic first came to light, treatment options for those infected have come a long way. During January 2021, the FDA approved ViiV Healthcare’s Cabenuva as the very first once-a-month injection for HIV patients. But the Research Triangle pharma is not satisfied yet.
